Janssen-Cilag discontinues Comfyde for epilepsy
This article was originally published in Scrip
Executive Summary
Janssen-Cilag (Johnson & Johnson) has withdrawn an EU marketing application for its troubled anticonvulsant Comfyde (carisbamate) for the treatment of partial onset seizures in patients with epilepsy and discontinued developing it for the treatment of epilepsy.